Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL® 2 study

Name: Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL® 2 study
Creator: Kenneth Gordon
Published: 2025-02-28T16:13:45.748Z
Keywords: Psoriasis

Gordon, Kenneth; Augustin, Matthias; Barker, Jonathan; Tada, Yayoi; Lebwohl, Mark; Tang, Ming; Hofmann, Patrick; Thoma, Christian; Gottlieb, Alice

doi:10.17632/x4bmwhd8h6.4

Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL® 2 study

Published: 28 February 2025| Version 4 | DOI: 10.17632/x4bmwhd8h6.4

Contributors:

Kenneth Gordon, Matthias Augustin, Jonathan Barker, Yayoi Tada, Mark Lebwohl, Ming Tang, Patrick Hofmann, Christian Thoma, Alice Gottlieb

Description

Supplement material for "Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL® 2 study", published in the Journal of the American Academy of Dermatology (https://doi.org/10.1016/j.jaad.2025.01.089)

Files

Funding

Boehringer Ingelheim (Germany)

Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL® 2 study

Description

Files

Categories

Funding

Licence